Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

经动脉化疗栓塞联合微波消融与单用微波治疗中型肝细胞癌

卷 22, 期 1, 2022

发表于: 20 January, 2022

页: [77 - 85] 页: 9

弟呕挨: 10.2174/1568009622666220117094146

价格: $65

摘要

背景与目的：肝细胞癌 (HCC) 是第五大常见癌症，也是癌症相关死亡的第二大原因。 HCC 和肝硬化的唯一确定性治疗方法是肝移植，但在某些地区等待时间长且供体器官数量相对固定会对肝移植的可及性产生负面影响。这项工作的目的是评估和比较单独接受经皮微波消融 (MWA) 和联合 TACE 的中型 HCC 患者的短期结果。 方法：本前瞻性研究纳入 40 例中型 HCC 病灶患者，分为两组； A 组包括 20 名患者接受 TACE 治疗，然后在 2 周后经皮 MWA 治疗，B 组包括 20 名患者接受 2 次经皮 MWA 治疗，间隔 2 周。从两组获得完整的病史采集、临床检查、实验室检查、腹部超声检查和腹部三相计算机断层扫描 (CT) 造影。在治疗后1个月和3个月对病例进行实验室和放射学随访。 结果：在开始治疗前，两个研究组的病例在社会人口学标准、实验室测量和临床标准方面没有统计学上的显着差异。联合治疗组的反应略好，但没有显示出统计学上的显着差异。 MWA组并发症发生率较高。 结论：肝细胞癌是HCV相关肝硬化的常见并发症。 TACE-MWA 的联合导致比 MWA 更好的反应率和更少的并发症。

关键词: 微波消融，经动脉化疗栓塞，肝细胞癌，死亡率，并发症，复发

« Previous Next »
图形摘要

[1]
Dimitroulis, D.; Damaskos, C.; Valsami, S.; Davakis, S.; Garmpis, N.; Spartalis, E.; Athanasiou, A.; Moris, D.; Sakellariou, S.; Kykalos, S.; Tsourouflis, G.; Garmpi, A.; Delladetsima, I.; Kontzoglou, K.; Kouraklis, G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J. Gastroenterol., 2017, 23(29), 5282-5294.
[http://dx.doi.org/10.3748/wjg.v23.i29.5282] [PMID: 28839428]
[2]
El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, 142(6), 1264-1273.
[http://dx.doi.org/10.1053/j.gastro.2011.12.061]
[3]
Elgamal, S.; Ghafar, A.A.; Ghoneem, E.; Elshaer, M.; Alrefai, H.; Elemshaty, W. Characterization of patients with hepatocellular carcinoma on the way for early detection: one center experience. Egypt. J. Intern. Med., 2018, 30(4), 231-238.
[http://dx.doi.org/10.4103/ejim.ejim_29_18]
[4]
Abdelaziz, A.O.; Nabeel, M.M.; Elbaz, T.M.; Shousha, H.I.; Hassan, E.M.; Mahmoud, S.H.; Rashed, N.A.; Ibrahim, M.M.; Abdelmaksoud, A.H. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: Prospective analysis. Scand. J. Gastroenterol., 2015, 50(4), 479-484.
[http://dx.doi.org/10.3109/00365521.2014.1003397] [PMID: 25592058]
[5]
Kuang, M.; Xie, X-Y.; Huang, C.; Wang, Y.; Lin, M-X.; Xu, Z-F.; Liu, G.J.; Lu, M.D. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J. Gastrointest. Surg., 2011, 15(12), 2165-2171.
[http://dx.doi.org/10.1007/s11605-011-1716-2] [PMID: 21972056]
[6]
Abdelaziz, A.; Elbaz, T.; Shousha, H.I.; Mahmoud, S.; Ibrahim, M.; Abdelmaksoud, A.; Nabeel, M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: An Egyptian multidisciplinary clinic experience. Surg. Endosc., 2014, 28(12), 3429-3434.
[http://dx.doi.org/10.1007/s00464-014-3617-4] [PMID: 24935203]
[7]
Abdelaziz, A.O.; Elbaz, T.M.; Shousha, H.I.; Ibrahim, M.M.; Rahman El-Shazli, M.A.; Abdelmaksoud, A.H.; Aziz, O.A.; Zaki, H.A.; Elattar, I.A.; Nabeel, M.M. Survival and prognostic factors for hepatocellular carcinoma: An Egyptian multidisciplinary clinic experience. Asian Pac. J. Cancer Prev., 2014, 15(9), 3915-3920.
[http://dx.doi.org/10.7314/APJCP.2014.15.9.3915] [PMID: 24935574]
[8]
Tanaka, M.; Ando, E.; Simose, S.; Hori, M.; Kuraoka, K.; Ohno, M.; Yutani, S.; Harada, K.; Sata, M. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol. Res., 2014, 44(2), 194-200.
[http://dx.doi.org/10.1111/hepr.12100] [PMID: 23521520]
[9]
Ginsburg, M.; Zivin, S.P.; Wroblewski, K.; Doshi, T.; Vasnani, R.J.; Van Ha, T.G. Comparison of combination therapies in the management of hepatocellular carcinoma: Transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J. Vasc. Interv. Radiol., 2015, 26(3), 330-341.
[http://dx.doi.org/10.1016/j.jvir.2014.10.047] [PMID: 25534635]
[10]
Bruix, J.; Sherman, M. Management of hepatocellular carcinoma: An update. Hepatology, 2011, 53(3), 1020-1022.
[http://dx.doi.org/10.1002/hep.24199] [PMID: 21374666]
[11]
Minami, Y.; Kudo, M.; Chung, H.; Kawasaki, T.; Yagyu, Y.; Shimono, T.; Shiozaki, H. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am. J. Roentgenol., 2007, 188(2), 489-494.
[http://dx.doi.org/10.2214/AJR.05.1286] [PMID: 17242259]
[12]
Ma, Y.; Zhang, X.; Li, X.; Zhang, L.; Su, H.; Zhan, C. Value of computed tomography and magnetic resonance imaging in diagnosis and differential diagnosis of small hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao, 2008, 28(12), 2235-2238.
[13]
Abdelaziz, A.O.; Abdelmaksoud, A.H.; Nabeel, M.M.; Shousha, H.I.; Cordie, A.A.; Mahmoud, ShH.; Medhat, E.; Omran, D.; Elbaz, T.M. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2017, 18(1), 189-194.
[PMID: 28240516]
[14]
EI-Edel, RH; Tawfik, GA; Noreldin, RI; El-Jaky, MA; Eisaa, DA Evaluation of serum Midkine as a novel marker in hepatocellular carcinomas. Menoufia Med. J., 2018, 31(3), 1094.
[15]
Shaheen, K.Y.; Abdel-Mageed, A.I.; Safwat, E.; AlBreedy, A.M. The value of serum midkine level in diagnosis of hepatocellular carcinoma. Int. J. Hepatol., 2015, 2015, 146389.
[http://dx.doi.org/10.1155/2015/146389]
[16]
Abozaid, S.R.; Elshamy, M.H.; Alazim, A.A.; Elhawari, S.A. Microwave ablation and/or transcatheter arterial chemo-embolization in the treatment of hepatocellular carcinoma. AJIED, 2020, 10(4), 407-416.
[http://dx.doi.org/10.21608/aeji.2020.25284.1054]
[17]
Smolock, A.R.; Cristescu, M.M.; Hinshaw, A.; Woo, K.M.; Wells, S.A.; Ziemlewicz, T.J.; Lubner, M.G.; Dalvie, P.S.; Louis Hinshaw, J.; Brace, C.L.; Ozkan, O.S.; Lee, F.T., Jr; Laeseke, P. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom. Radiol. (N.Y.), 2018, 43(9), 2497-2504.
[http://dx.doi.org/10.1007/s00261-018-1464-9] [PMID: 29450606]
[18]
Xu, L.F.; Sun, H.L.; Chen, Y.T.; Ni, J.Y.; Chen, D.; Luo, J.H.; Zhou, J.X.; Hu, R.M.; Tan, Q.Y. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J. Gastroenterol. Hepatol., 2013, 28(3), 456-463.
[http://dx.doi.org/10.1111/jgh.12088] [PMID: 23216261]
[19]
Mazure, N.M.; Chauvet, C.; Bois-Joyeux, B.; Bernard, M-A.; Nacer-Chérif, H.; Danan, J-L. Repression of α-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: Characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res., 2002, 62(4), 1158-1165.
[PMID: 11861398]
[20]
Memon, K.; Kulik, L.; Lewandowski, R.J.; Wang, E.; Ryu, R.K.; Riaz, A.; Nikolaidis, P.; Miller, F.H.; Yaghmai, V.; Baker, T.; Abecassis, M.; Benson, A.B., III; Mulcahy, M.F.; Omary, R.A.; Salem, R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. J. Hepatol., 2012, 56(5), 1112-1120.
[http://dx.doi.org/10.1016/j.jhep.2011.11.020] [PMID: 22245905]
[21]
He, C.; Zhang, X.; Li, C.; Peng, W.; Wen, T-F.; Yan, L-N.; Yang, J.; Lu, W. Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization. Oncotarget, 2017, 8(49), 85599-85611.
[http://dx.doi.org/10.18632/oncotarget.20343] [PMID: 29156744]
[22]
Li, W.; Man, W.; Guo, H.; Yang, P. Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of advanced hepatocellular carcinoma. J. Cancer Res. Ther., 2016, 12(7)(Suppl.), C217-C220.
[http://dx.doi.org/10.4103/0973-1482.200598] [PMID: 28230020]
[23]
Goldberg, S.N.; Saldinger, P.F.; Gazelle, G.S.; Huertas, J.C.; Stuart, K.E.; Jacobs, T.; Kruskal, J.B. Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology, 2001, 220(2), 420-427.
[http://dx.doi.org/10.1148/radiology.220.2.r01au44420] [PMID: 11477246]
[24]
Mostafa, E.M.; Ganguli, S.; Faintuch, S.; Mertyna, P.; Goldberg, S.N. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J. Vasc. Interv. Radiol., 2008, 19(12), 1740-1748.
[http://dx.doi.org/10.1016/j.jvir.2008.08.028] [PMID: 18951042]
[25]
Guo, J.; Wang, S.; Han, Y.; Jia, Z.; Wang, R. Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. Oncol. Lett., 2021, 22(1), 554.
[http://dx.doi.org/10.3892/ol.2021.12815] [PMID: 34084221]
[26]
Liu, H-C.; Shan, E-B.; Zhou, L.; Jin, H.; Cui, P-Y.; Tan, Y.; Lu, Y.M. Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects. Chin. J. Cancer Res., 2014, 26(4), 471-477.
[PMID: 25232222]
[27]
Bharadwaz, A.; Bak-Fredslund, K.P.; Villadsen, G.E.; Nielsen, J.E.; Simonsen, K.; Sandahl, T.D.; Grønbæk, H.; Nielsen, D.T. Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: Experience from a Danish tertiary liver center. Acta Radiol., 2016, 57(7), 844-851.
[http://dx.doi.org/10.1177/0284185115603246] [PMID: 26342009]
[28]
Xu, C.; Lv, P-H.; Huang, X-E.; Wang, S-X.; Sun, L.; Wang, F-A. Efficacy of transarterial chemoembolization combined with radiofrequency ablation in treatment of hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2015, 16(14), 6159-6162.
[http://dx.doi.org/10.7314/APJCP.2015.16.14.6159] [PMID: 26320512]
[29]
Chen, Q-W.; Ying, H-F.; Gao, S.; Shen, Y-H.; Meng, Z-Q.; Chen, H.; Chen, Z.; Teng, W.J. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol., 2016, 40(3), 309-314.
[http://dx.doi.org/10.1016/j.clinre.2015.07.008] [PMID: 26428660]
[30]
Liao, M.; Huang, J.; Zhang, T.; Wu, H. Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: A meta-analysis. PLoS One, 2013, 8(7), e68453.
[http://dx.doi.org/10.1371/journal.pone.0068453] [PMID: 23844203]
[31]
Clark, T.W.I. Complications of hepatic chemoembolization. Semin. Intervent. Radiol., 2006, 23(2), 119-125.
[32]
Bertot, L.C.; Sato, M.; Tateishi, R.; Yoshida, H.; Koike, K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: A systematic review. Eur. Radiol., 2011, 21(12), 2584-2596.
[http://dx.doi.org/10.1007/s00330-011-2222-3] [PMID: 21858539]
[33]
Poggi, G.; Tosoratti, N.; Montagna, B.; Picchi, C. Microwave ablation of hepatocellular carcinoma. World J. Hepatol., 2015, 7(25), 2578-2589.
[http://dx.doi.org/10.4254/wjh.v7.i25.2578] [PMID: 26557950]
[34]
Liu, C.; Liang, P.; Liu, F.; Wang, Y.; Li, X.; Han, Z.; Liu, C. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int. J. Hyperthermia, 2011, 27(7), 654-662.
[http://dx.doi.org/10.3109/02656736.2011.605099] [PMID: 21966941]
[35]
Negm, O.; Abou Saif, S.; El Gharib, M.; Yousef, M.; Abd-Elsalam, S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 2017, 29(3), 317-321.
[http://dx.doi.org/10.1097/MEG.0000000000000790] [PMID: 27893491]
[36]
Watany, M.; Badawi, R.; Elkhalawany, W.; Abd-Elsalam, S. Study of Dickkopf-1 (DKK-1) Gene Expression in Hepatocellular Carcinoma Patients. J. Clin. Diagn. Res., 2017, 11(2), OC32-OC34.
[http://dx.doi.org/10.7860/JCDR/2017/23095.9450] [PMID: 28384913]
[37]
Abdelfattah, A.A.M.; Rizk, F.; Hawash, N.; Hanafy, A.; El-Kalla, F.; Abd-Elsalam, S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int. J. Hyperthermia, 2018, 34(8), 1367-1371.
[http://dx.doi.org/10.1080/02656736.2018.1424946] [PMID: 29308685]
[38]
El-Gebaly, F.; Abou-Saif, S.; Elkadeem, M.; Helmy, A.; Abd-Elsalam, S.; Yousef, M.; Elkhouly, R.A.; Amer, I.F.; El-Demerdash, T. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in Egyptian patients. Curr. Cancer Drug Targets, 2019, 19(11), 896-905.
[http://dx.doi.org/10.2174/1568009619666190718141647] [PMID: 31538897]
[39]
Badawi, R.; Soliman, H.; Ziada, D. Serum markers as a predictor of hepatic fibrosis compared to fibroscan in chronic hepatitis B infected Egyptian patients: A cross-sectional study. Open Biomark. J., 2020, 10, 69-75.
[http://dx.doi.org/10.2174/1875318302010010069]
[40]
Mohamed, A.A.; El-Toukhy, N.; Ghaith, D.M. Talin-1 gene expression as a tumor marker in hepatocellular carcinoma patients: A pilot study. Open Biomark. J., 2020, 10, 15-22.
[http://dx.doi.org/10.2174/1875318302010010015]

Rights & Permissions Print Cite
Article Metrics
37
1
© 2024 Bentham Science Publishers | Privacy Policy